Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-04-29 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物独立董事提名人声明-王广基
Board/Management Information Classification · 95% confidence The document is a formal statement nominating an independent director candidate for the company's board. It details the qualifications, independence criteria, and compliance with regulatory requirements for the nominee. There is no financial data, no report of financial results, no voting results, no meeting materials, and no mention of any report publication. The content is focused on board/management information, specifically the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and does not indicate it is an announcement of a report or a certification. Hence, the classification is MANG with high confidence.
2022-04-29 Chinese
前沿生物独立董事提名人声明-KAI CHEN（陈凯）
Board/Management Information Classification · 95% confidence The document is a formal statement nominating an independent director candidate for the company's board. It details the qualifications, independence criteria, and compliance with regulatory requirements for the nominee. There is no financial data, no report or results announcement, and no mention of voting results or meeting materials. The document is a declaration related to board/management changes, specifically the nomination of a board member. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on nomination, not a full report or announcement of voting results.
2022-04-29 Chinese
前沿生物关于2022年度以简易程序向特定对象发行股票摊薄即期回报的风险提示及填补措施和相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company regarding a specific stock issuance event using a simplified procedure to certain investors. It includes risk warnings about dilution of immediate returns, financial impact analysis with detailed assumptions and projections, explanations of the necessity and rationale for the issuance, descriptions of the use of proceeds, and commitments from the board, senior management, and controlling shareholder to measures mitigating dilution risks. The document references regulatory requirements and compliance with securities laws. It is not a full annual or quarterly financial report, nor an earnings release or audit report. It is not a proxy statement or voting result announcement. It is a capital raising event with detailed disclosure about the issuance and related risk and mitigation measures. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2022-04-29 Chinese
前沿生物关于2022年度以简易程序向特定对象发行A股股票预案披露的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (692 characters) regarding a 2022 plan for a simplified procedure to issue A shares to specific investors. It references board meetings approving the plan and mentions that related detailed documents are disclosed on the stock exchange website. The text explicitly states this is a "提示性公告" (a notice or announcement) about the issuance plan, not the issuance itself or detailed financial data. There is no financial statement or detailed report content here, only an announcement of a capital raising plan. Therefore, this fits the category of Capital/Financing Update (CAP).
2022-04-29 Chinese
前沿生物2022年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年第一季度报告' which translates to '2022 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2022. The report is unaudited as indicated. The content includes comprehensive financial statements and analysis for a period shorter than a full fiscal year, which fits the definition of an Interim / Quarterly Report (IR). The document length is over 13,000 characters, indicating it is the full report, not just an announcement or summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2022
2022-04-29 Chinese
前沿生物董事会审计委员会2021年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2021年度履职情况报告" (2021 Annual Performance Report) of the Board Audit Committee of a listed company. It details the audit committee's activities, meetings, supervision of external and internal audits, review of financial reports, and internal control evaluations for the year 2021. The content focuses on the audit committee's work and oversight rather than presenting full financial statements or comprehensive company financial performance. The document length is 2374 characters, which is relatively short and more of a committee report rather than a full audit report or annual report. It is not a certification or a brief announcement but a detailed report on audit committee activities. This fits best with the category of Audit Report / Information (AR), which includes standalone audit reports and related audit committee reports. Therefore, the classification is AR with high confidence. FY 2021
2022-04-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.